A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Prostate Cancer|Adenocarcinoma
DRUG: Atrasentan
Adverse events, Every 12 weeks|Serious adverse events|Oncology-related events (OREs)|Deaths|Study drug exposure|Change from baseline in Karnofsky performance status|Vital signs|Stratification by treatment group from prior study
Safety and laboratory parameters, Every 12 weeks
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.